SCHEMBL664284

SCHEMBL664284

O=C(O)C1CCC(c2ccccc2)CC1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.79
RAB9A P51151 1/20 0.79
AKR1C3 P42330 1/20 0.78
AKR1C1 Q04828 1/20 0.78
DEGS1 O15121 1/20 0.50
SIGMAR1 Q99720 2/20 0.48
SLC18A3 Q16572 2/20 0.48
PDE4A P27815 1/20 0.44
PDE4B Q07343 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44
DGAT1 O75907 1/20 0.43
SOAT1 P35610 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
NOTUM Q6P988 1/20 0.43
GRIN2B Q13224 1/20 0.43
ALDH1A1 P00352 1/20 0.43
IDO1 P14902 1/20 0.43
HTR2B P41595 1/20 0.43
FFAR2 O15552 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3516198 1.00 NPC1 (0.79) NPC1RAB9AAKR1C3AKR1C1DEGS1
SCHEMBL2511695 1.00 NPC1 (0.79) NPC1RAB9AAKR1C3AKR1C1DEGS1
Hydrochloric Acid SCHEMBL10892943 0.98 NPC1 (0.76) NPC1RAB9AAKR1C3AKR1C1DEGS1
SCHEMBL4444928 0.98 NPC1 (0.76) NPC1RAB9AAKR1C3AKR1C1DEGS1
SCHEMBL4449225 0.98 NPC1 (0.76) NPC1RAB9AAKR1C3AKR1C1DEGS1
SCHEMBL27478716 0.98 NPC1 (0.76) NPC1RAB9AAKR1C3AKR1C1DEGS1
SCHEMBL3278764 0.88 NPC1 (1.00) NPC1RAB9AAKR1C3AKR1C1DEGS1
SCHEMBL1073107 0.88 AKR1C3 (1.00) NPC1RAB9AAKR1C3AKR1C1DEGS1
SCHEMBL26144401 0.88 AKR1C3 (1.00) NPC1RAB9AAKR1C3AKR1C1DEGS1
SCHEMBL17811172 0.88 AKR1C3 (1.00) NPC1RAB9AAKR1C3AKR1C1DEGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3688124-B1 ESTER COMPOUNDS, LUBRICATING OIL COMPOSITIONS CONTAINING SAME AND PROCESSES FOR MAKING SAME EXXONMOBIL CHEMICAL PATENTS INC (US) 2023-10-25 EP claimed
CN-116082289-A 4-R-phenylcyclohexyl formaldehyde ethylene glycol and preparation method thereof 河北凡克新材料有限公司 2023-05-09 CN claimed
EP-2185007-B1 MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS GIVAUDAN SA (CH) 2018-05-23 EP claimed
US-20160205978-A1 MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS GIVAUDAN SA (CH) 2016-07-21 US claimed
US-20100311786-A1 MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS GIVAUDAN SA (CH) 2010-12-09 US claimed
EP-2185007-A2 MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS Givaudan SA (CH) 2010-05-19 EP claimed
WO-2009015504-A2 MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS GIVAUDAN SA (CH) 2009-02-05 WO claimed
EP-1171511-B1 A PROCESS FOR PRODUCING POLY(ARYLENE SULFIDE) CONOCOPHILLIPS CO (US) 2006-04-19 EP claimed
US-5179193-A From dihaloaromatic sulfone, polyhalodiarylsulfone and polymerizable sulfur source; coatings, films, moldings, fibers PHILLIPS PETROLEUM COMPANY (US) 1993-01-12 US claimed
US-5177174-A Branched aromatic sulfide/sulfone polymer production PHILLIPS PETROLEUM COMPANY (US) 1993-01-05 US claimed
JP-1075445-A None JP disclosed
CN-122029148-A N-phenyl-3- (2, 5-dioxopyrrolidin-1-yl) propionamide derivatives and similar compounds as DUX4 inhibitors for the treatment of, for example, neuromuscular diseases 阿勒泰治疗公司 2026-05-12 CN disclosed
US-12162871-B2 Inhibitors of VAP-1 ACUCELA INC. (US) 2024-12-10 US disclosed
EP-3688124-B1 ESTER COMPOUNDS, LUBRICATING OIL COMPOSITIONS CONTAINING SAME AND PROCESSES FOR MAKING SAME EXXONMOBIL CHEMICAL PATENTS INC (US) 2023-10-25 EP disclosed
US-11787791-B2 Inhibitors of VAP-1 ACUCELA INC. (US) 2023-10-17 US disclosed
JP-S6475445-A PRODUCTION OF 4'-HYDROXYBIPHENYL-4-CARBOXYLIC ACID MITSUI TOATSU CHEMICALS 1989-03-22 JP disclosed
EP-0272580-A2 Liquidcrystalline cyclohexylbenzene derivatives their manufacturing and novel nematic admixtures containing same Wojskowa Akademia Techniczna im. Jaroslawa Dabrowskiego (PL) 1988-06-29 EP disclosed
EP-0233267-A1 SMECTIC CRYSTAL PHASES. MERCK PATENT GMBH (DE) 1987-08-26 EP disclosed
WO-1987001717-A2 SMECTIC CYSTAL PHASES MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1987-03-26 WO disclosed
US-4109015-A PROSTAGLANDINS, LUTEOLYTIC IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1978-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787791-B2 Inhibitors of VAP-1 VAPB, VAPA, TOE1 NPC1 198/4885RAB9A 829/4885AKR1C3 4526/4885
US-20100311786-A1 MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS SORD, GLUL, ASNS NPC1 2443/4885RAB9A 2876/4885AKR1C3 1058/4885
US-12162871-B2 Inhibitors of VAP-1 VAPB, VAPA, TOE1 NPC1 198/4885RAB9A 829/4885AKR1C3 4526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.